Dexcom Stelo Wins FDA Approval as First Prescription-Free OTC Continuous Glucose Monitor for Non-Insulin Users

August 17, 2026

Dexcom (via Facebook) USA

Overview

Dexcom’s Stelo glucose biosensor system has received FDA approval as the first over-the-counter (OTC) continuous glucose monitor (CGM) for adults aged 18 and older who do not use insulin. This landmark decision expands the CGM market beyond traditional diabetes management into the broader wellness and metabolic health sector, allowing users to track glucose levels for up to 15 days to understand the impact of diet, exercise, and sleep. This move is poised to accelerate the adoption of CGM technology among pre-diabetic individuals and health-conscious consumers.

In Depth

Key Findings

Dexcom has announced that its Stelo glucose biosensor system has secured U.S. Food and Drug Administration (FDA) approval as the first over-the-counter (OTC) continuous glucose monitoring (CGM) system for adults aged 18 and older who do not use insulin. This approval represents a pivotal shift, significantly broadening access to CGM technology and extending its utility beyond clinical diabetes management into the expansive wellness market.

Technical/Clinical Details

The Stelo system comprises a compact, wearable sensor designed for continuous wear for up to 15 days. It provides real-time glucose readings, offering personalized insights into how daily activities such as diet, exercise, and sleep affect blood sugar levels. This empowers individuals not on insulin therapy to gain a deeper understanding of their metabolic health, thereby facilitating data-driven lifestyle improvements. Historically, CGM devices have been prescription-only and primarily targeted insulin-dependent diabetic patients; Stelo’s OTC status makes it accessible to a wider general consumer base focused on proactive health management.

Background & Context

Previously, CGM devices required a doctor’s prescription, limiting their use predominantly to individuals with diagnosed diabetes who require insulin. The OTC approval for Stelo dramatically expands the potential target demographic for CGM, encompassing hundreds of millions of non-diabetic adults, including those with pre-diabetes or a strong interest in actively managing their health. This development is symptomatic of a larger trend where digital health and wearable technologies are increasingly integrated into personal health care, shifting focus from reactive treatment to proactive wellness. Market analytics consistently show the non-invasive glucose monitoring sector on a steep growth trajectory, and OTC products like Stelo are expected to fuel this expansion further, potentially mirroring the market impact of fitness trackers or smartwatches.

Strategic Significance & Outlook

The Stelo approval is strategically significant for Dexcom, reinforcing its leadership in the CGM market. By entering the wellness market, Dexcom is poised to diversify its revenue streams and capture a substantial new market segment, complementing its existing product portfolio for diabetic patients. While competitors are also exploring OTC pathways, Dexcom’s early entry establishes a crucial first-mover advantage. In the long term, the vast amount of real-world metabolic data generated by such widespread use could drive the development of advanced AI-powered personalized health coaching and preventative disease programs, revolutionizing how individuals interact with their health data and preventive medicine.

Source: https://www.facebook.com/dexcom/posts/the-stelo-by-dexcom-glucose-biosensor-has-been-reimagined-to-help-people-with-or/1548825923955120/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.